No­var­tis broad­ens BRAF/MEK can­cer com­bo use, win­ning tu­mor-ag­nos­tic ap­proval in pa­tients 6 and up

No­var­tis nabbed an­oth­er FDA win for its Tafin­lar and Mekin­ist can­cer com­bo, this time broad­en­ing its la­bel quite wide­ly.

US reg­u­la­tors green­light­ed the ther­a­py for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER